Patent intelligence · US
US 11807638
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
Patent details — US 11807638
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 7, 2023
- Expiration
- Nov 2, 2043
- Applicant
- Enliven Inc.
- Claims
- 44
- CPC classes
- A61K, A61K31/437, A61K31/444, A61K31/496
Quick answer
US 11807638 (5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases) is held by Enliven Inc.. Status: granted. Granted Nov 7, 2023. Expires Nov 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enliven Inc.
- Grant date
- Expiration
- Claims
- 44
- CPC classes
- A61K, A61K31/437, A61K31/444, A61K31/496, A61K31/4995, A61K31/501
More from Enliven Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12240846
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11807649
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
granted -
US 11767321
5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
granted -
US 10888597
Composition for treating brain stroke
granted
Related coverage
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
Generic Oncology Drugs in Egypt: Market Analysis & Regional Impact
This article delves into the market dynamics of generic oncology drugs in Egypt, highlighting their role in cancer treatment and regional healthcare impact.
Frequently asked questions
What is US patent 11807638?
US 11807638 (5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases) is held by Enliven Inc.. Status: granted. Granted Nov 7, 2023. Expires Nov 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11807638?
Enliven Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11807638 expire?
Our index shows an expiration date of Nov 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.